LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

8.31 -0.24

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.18

Максимум

8.44

Ключови измерители

By Trading Economics

Приходи

-491K

-12M

EPS

-0.14

Служители

42

EBITDA

-779K

-13M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+240.5% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

727M

Предишно отваряне

8.55

Предишно затваряне

8.31

Настроения в новините

By Acuity

100%

0%

4 / 382 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.05.2025 г., 19:39 ч. UTC

Значими двигатели на пазара

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16.05.2025 г., 23:18 ч. UTC

Топ новини

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16.05.2025 г., 22:30 ч. UTC

Топ новини

U.S. Loses Last Triple-A Credit Rating -- Update

16.05.2025 г., 21:56 ч. UTC

Пазарно говорене

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16.05.2025 г., 21:56 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

16.05.2025 г., 21:54 ч. UTC

Топ новини

U.S. Loses Last Triple-A Credit Rating -- WSJ

16.05.2025 г., 21:22 ч. UTC

Пазарно говорене

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16.05.2025 г., 21:17 ч. UTC

Пазарно говорене

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16.05.2025 г., 21:17 ч. UTC

Топ новини

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16.05.2025 г., 21:05 ч. UTC

Пазарно говорене

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16.05.2025 г., 20:55 ч. UTC

Придобивния, сливания и поглъщания

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16.05.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Financial Services Roundup: Market Talk

16.05.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

16.05.2025 г., 20:37 ч. UTC

Топ новини

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16.05.2025 г., 20:33 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16.05.2025 г., 20:30 ч. UTC

Придобивния, сливания и поглъщания

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16.05.2025 г., 20:18 ч. UTC

Топ новини

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16.05.2025 г., 20:16 ч. UTC

Топ новини

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16.05.2025 г., 20:15 ч. UTC

Печалби

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16.05.2025 г., 20:11 ч. UTC

Придобивния, сливания и поглъщания

Henry Schein: William K. Daniel Joins Board

16.05.2025 г., 20:10 ч. UTC

Придобивния, сливания и поглъщания

Henry Schein: Strategic Investment by KKR Completed

16.05.2025 г., 20:05 ч. UTC

Придобивния, сливания и поглъщания

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16.05.2025 г., 19:38 ч. UTC

Пазарно говорене

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16.05.2025 г., 19:07 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures End Week Lower -- Market Talk

16.05.2025 г., 18:51 ч. UTC

Топ новини

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16.05.2025 г., 18:41 ч. UTC

Придобивния, сливания и поглъщания

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16.05.2025 г., 18:37 ч. UTC

Пазарно говорене

Gold Futures End Week on Negative Note -- Market Talk

16.05.2025 г., 18:35 ч. UTC

Топ новини

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16.05.2025 г., 18:32 ч. UTC

Топ новини

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16.05.2025 г., 18:28 ч. UTC

Пазарно говорене

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

240.5% нагоре

12-месечна прогноза

Среден 28.5 USD  240.5%

Висок 42 USD

Нисък 15 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

2

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

4 / 382 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.